GlassScriptPhysician profile
Dale A Klein
NPI 1215048277
$3,040.33
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $569 · 2021: $589 · 2022: $624 · 2023: $625 · 2024: $24.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $601.18 | 2019-2023 | Mounjaro, Jardiance |
| Amgen INC. | $432.04 | 2019-2023 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $321.11 | 2019-2021 | |
| Pfizer INC. | $271.34 | 2019-2023 | |
| Astellas Pharma US INC | $183.56 | 2019-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $168.48 | 2019-2021 | |
| Novo Nordisk INC | $152.54 | 2021-2022 | |
| Allergan, INC. | $143.59 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.50 | 2019-2023 | Ofev, Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $132.66 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $129.18 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $80.92 | 2021-2023 | |
| Daiichi Sankyo INC. | $80.69 | 2022-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $68.25 | 2019-2023 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $54.73 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $20.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.63 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $14.75 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $11.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.